Short-term toxicity study of 1-aminobenzotraizole, a CYP inhibitor, in Wistar rats

References

• Balani, S.K., et al., 2002. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 30 (10), 1059–1062.
   PubMed Web of Science ®Google Scholar
• Balani, S.K., et al., 2004. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 32 (10), 1092–1095.
   PubMed Web of Science ®Google Scholar
• Boily, M.O., et al., 2015. In vitro and in vivo mechanistic studies toward understanding the role of 1-aminobenzotriazole in rat drug–drug interactions. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 43 (12), 1960–1965.
   PubMed Web of Science ®Google Scholar
• Brody, S. and Wiqvist, N., 1961. Ovarian hormones and uterine growth: effects of estradiol, progesterone and relaxin on cell growth and cell division in the rat uterus. Endocrinology, 68 (6), 971–977.
   Web of Science ®Google Scholar
• Bruce, J.I. and Elliott, A.C., 2000. Pharmacological evaluation of the role of cytochrome P450 in intracellular calcium signalling in rat pancreatic acinar cells. British Journal of Pharmacology, 131 (4), 761–771.
   PubMed Web of Science ®Google Scholar
• Bruce A.M., et al., In vivo inhibition of oxidative drug metabolism by, and acute toxicity of, 1-aminobenzotriazole (ABT). Biochemical pharmacology, 37.13 (1988): 2515–2519.
   Google Scholar
• Campbell, C.D. and Rees, C.W., 1969. Reactive intermediates. Part I. Synthesis and oxidation of 1-and 2-aminobenzotriazole. Journal of the Chemical Society C: Organic, 5 (5), 742–747.
   Google Scholar
• Chiang, J.Y., 1998. Regulation of bile acid synthesis. Frontiers in Bioscience: A Journal and Virtual Library, 3, d176–d193.
   PubMedGoogle Scholar
• Colby, H.D., et al., 1995. Inactivation of adrenal cytochromes P450 by 1-aminobenzotriazole: divergence of in vivo and in vitro actions. Biochemical Pharmacology, 49 (8), 1057–1062.
   PubMed Web of Science ®Google Scholar
• Forman, W.B. and Barnhart, M.I., 1964. Cellular site for fibrinogen synthesis. JAMA, 187 (2), 128–132.
   PubMed Web of Science ®Google Scholar
• De Montellano, P.O. and Mathews, J.M., 1981. Autocatalytic alkylation of the cytochrome P-450 prosthetic haem group by 1-aminobenzotriazole. Isolation of an NN-bridged benzyne-protoporphyrin IX adduct. The Biochemical Journal, 195 (3), 761–764.
   PubMed Web of Science ®Google Scholar
• El-Kattan, A.F., et al., 2008. The use of 1-aminobenzotriazole in differentiating the role of CYP-mediated first pass metabolism and absorption in limiting drug oral bioavailability: a case study. Drug Metabolism Letters, 2 (2), 120–124.
   PubMedGoogle Scholar
• Emoto, C., et al., 2003. In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. Drug Metabolism and Pharmacokinetics, 18 (5), 287–295.
   PubMedGoogle Scholar
• Goyal, V., et al., 2019, Toxicologic and pathologic evaluation of cytochromes P450 inhibition by 1-aminobenzotriazole following repeated oral administration in Wistar rats. The Toxicologist, Supplement to Toxicological Sciences, 168 (1), Abstract #1440, 11. March 2019.
   Google Scholar
• Isayama, F., et al., 2003. The CYP inhibitor 1-aminobenzotriazole does not prevent oxidative stress associated with alcohol-induced liver injury in rats and mice. Free Radical Biology & Medicine, 35 (12), 1568–1581.
   PubMed Web of Science ®Google Scholar
• Linder, C.D., Renaud, N.A., and Hutzler, J.M., 2009. Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific Cytochrome P450 inactivator?. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 37 (1), 10–13.
   PubMed Web of Science ®Google Scholar
• Luo, Y., Yang, X., and Shi, Q., 2016. The cytochrome P450 inhibitor SKF-525A disrupts autophagy in primary rat hepatocytes. Chemico-Biological Interactions, 255, 55–62.
   PubMed Web of Science ®Google Scholar
• Martinkova, M., Kubickova, B., and Stiborova, M., 2012. Effects of cytochrome P450 inhibitors on peroxidase activity. Neuro Endocrinology Letters, 33, 33–40.
   PubMed Web of Science ®Google Scholar
• Meschter, C.L., et al., 1994. A 13-week toxicologic and pathologic evaluation of prolonged cytochromes P450 inhibition by 1-aminobenzotriazole in male rats. Toxicological Sciences, 22 (3), 369–381.
   Google Scholar
• Mico, B.A., et al., 1988. In vivo inhibition of oxidative drug metabolism by, and acute toxicity of, 1-aminobenzotriazole (ABT). A tool for biochemical toxicology. Biochemical Pharmacology, 37 (13), 2515–2519.
   PubMed Web of Science ®Google Scholar
• Mugford, C.A., et al., 1992. 1-Aminobenzotriazole-induced destruction of hepatic and renal cytochromes P450 in male Sprague-Dawley rats. Toxicological Sciences, 19 (1), 43–49.
   Google Scholar
• National Research Council, 1985. Guide for the care and use of laboratory animals, 6th ed. Washington, DC : US Department of Health and Human Services.
   Google Scholar
• Sodhi, J.K., et al., 2014. 1-Aminobenzotriazole coincubated with (S)-warfarin results in potent inactivation of CYP2C9. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 42 (5), 813–817.
   PubMed Web of Science ®Google Scholar
• Subramanian, R., et al., 2014. P450-mediated O-demethylated metabolite is responsible for rat hepatobiliary toxicity of pyridyltriazine-containing PI3K inhibitors. Toxicological Sciences: An Official Journal of the Society of Toxicology, 142 (1), 298–310.
   PubMed Web of Science ®Google Scholar
• Thomas Sanderson, J., 2006. The steroid hormone biosynthesis pathway as a target for endocrine-disrupting chemicals. Toxicological Sciences: An Official Journal of the Society of Toxicology, 94 (1), 3–21.
   PubMed Web of Science ®Google Scholar
• Watanabe, A., et al., 2016. In vivo use of the CYP inhibitor 1-aminobenzotriazole to increase long-term exposure in mice. Biopharmaceutics & Drug Disposition, 37 (6), 373–378.
   PubMed Web of Science ®Google Scholar
• Yu, A.-M., et al., 2005. Potential role for human cytochrome P450 3A4 in estradiol homeostasis. Endocrinology, 146 (7), 2911–2919.
   PubMed Web of Science ®Google Scholar
• Zhang, L., et al., 2011. Dual effects of estrogen on vascular smooth muscle cells: receptor-mediated proliferative vs. metabolite-induced pro-senescent actions. Steroids, 76 (3), 309–316.
   PubMed Web of Science ®Google Scholar